Vevye patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8614178 NOVALIQ GMBH Pharmaceutical composition for treatment of dry eye syndrome
Dec, 2030

(7 years from now)

US10813976 NOVALIQ GMBH Ophthalmic compositions comprising ciclosporin
Sep, 2037

(14 years from now)

US11154513 NOVALIQ GMBH Semifluorinated compounds
Nov, 2038

(15 years from now)

US11413323 NOVALIQ GMBH Ophthalmic composition for treatment of dry eye disease
Oct, 2039

(16 years from now)

Vevye is owned by Novaliq Gmbh.

Vevye contains Cyclosporine.

Vevye has a total of 4 drug patents out of which 0 drug patents have expired.

Vevye was authorised for market use on 30 May, 2023.

Vevye is available in solution;ophthalmic dosage forms.

Vevye can be used as treatment of dry eye disease (ded), treatment of the signs and symptoms of dry eye disease (ded).

The generics of Vevye are possible to be released after 11 October, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of dry eye disease (ded)


More Information on Dosage

VEVYE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic